董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey Farrow | 男 | Director | 64 | 未披露 | 未持股 | 2026-07-02 |
| Richard Stewart | 男 | Director | 67 | 136.85万美元 | 80.25 | 2026-07-02 |
| Aaron Royston | 男 | Director | 42 | 未披露 | 未持股 | 2026-07-02 |
| Andrew D. Goldberg | 男 | Chief Executive Officer and Director and President | 45 | 未披露 | 未持股 | 2026-07-02 |
| Lucian Iancovici | 男 | Chairman of the Board and Director | 43 | 未披露 | 未持股 | 2026-07-02 |
| Nancy R. Phelan | 女 | Director | 57 | 24.13万美元 | 5.51 | 2026-07-02 |
| Thomas Sellig | 男 | Director | 59 | 13.94万美元 | 11.03 | 2026-07-02 |
| Reid Waldman | 男 | Director | 31 | 未披露 | 未持股 | 2026-07-02 |
| Jeffrey Farrow | 男 | Director | 64 | 未披露 | 未持股 | 2026-07-02 |
| Chris Martin | 男 | Director | 50 | 未披露 | 未持股 | 2026-07-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew D. Goldberg | 男 | Chief Executive Officer and Director and President | 45 | 未披露 | 未持股 | 2026-07-02 |
| Mark Oki | 男 | Chief Financial Officer | 57 | 101.54万美元 | 未持股 | 2026-07-02 |
| Erik Atkisson | 男 | Chief Legal Officer | 54 | 98.34万美元 | 未持股 | 2026-07-02 |
| Craig Donnelly | 男 | Chief Operations Officer | 49 | 未披露 | 未持股 | 2026-07-02 |
| Mark Rubinstein | 男 | Chief Medical Officer | 57 | 未披露 | 未持股 | 2026-07-02 |
董事简历
中英对照 | 中文 | 英文- Jeffrey Farrow
-
Jeffrey Farrow，2016年4月以来，他一直担任公司的首席财务官。他此前曾担任ZS Pharma, Inc.（生物制药公司，于2015年12月被Astra Zeneca 收购）的首席财务官。任职ZS Pharma 公司之前，他曾担任Hyperion Therapeutics, Inc.（一个商业制药公司）的首席财务官（2010年7月至2015年5月），在那里他曾担任团队成员，负责成功获得监管部门的批准，以及治疗尿素循环障碍的RAVICTI 成功商业发布。他此前曾担任Evotec AG（药物发现和开发公司）的财务副总裁。任职Evotec 公司之前，他曾担任Renovis, Inc.（药物发现和开发公司，被Evotec AG。收购）的财务副总裁兼首席会计官。职业生涯早期，他曾任职KPMG LLP，从事审计实践7年。他持有California State University at Fullerton 的工商管理学士学位（主修公司财务），也是注册会计师（非活跃）。于2021年4月19日获委任为三叶草生物制药有限公司独立非执行董事，自2021年9月26日起生效。
Jeffrey Farrow was appointed to the Board in October 2026. Mr. Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics in eye care and beyond, since April 2023. Mr. Farrow has also served as a director of Clover Biopharmaceuticals, Ltd., a development stage biotechnology company listed on the Hong Kong Stock Exchange, since September 2021 and a director, chairperson of the audit committee and member of the nominating and corporate governance committee of Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late stage specialty pharmaceutical company, since May 2026. Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc. (formerly Nasdaq: GBT), a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer Inc. Prior to that, Mr. Farrow served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 which was acquired by Horizon Therapeutics in May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive). - Jeffrey Farrow，2016年4月以来，他一直担任公司的首席财务官。他此前曾担任ZS Pharma, Inc.（生物制药公司，于2015年12月被Astra Zeneca 收购）的首席财务官。任职ZS Pharma 公司之前，他曾担任Hyperion Therapeutics, Inc.（一个商业制药公司）的首席财务官（2010年7月至2015年5月），在那里他曾担任团队成员，负责成功获得监管部门的批准，以及治疗尿素循环障碍的RAVICTI 成功商业发布。他此前曾担任Evotec AG（药物发现和开发公司）的财务副总裁。任职Evotec 公司之前，他曾担任Renovis, Inc.（药物发现和开发公司，被Evotec AG。收购）的财务副总裁兼首席会计官。职业生涯早期，他曾任职KPMG LLP，从事审计实践7年。他持有California State University at Fullerton 的工商管理学士学位（主修公司财务），也是注册会计师（非活跃）。于2021年4月19日获委任为三叶草生物制药有限公司独立非执行董事，自2021年9月26日起生效。
- Jeffrey Farrow was appointed to the Board in October 2026. Mr. Farrow has served as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics in eye care and beyond, since April 2023. Mr. Farrow has also served as a director of Clover Biopharmaceuticals, Ltd., a development stage biotechnology company listed on the Hong Kong Stock Exchange, since September 2021 and a director, chairperson of the audit committee and member of the nominating and corporate governance committee of Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late stage specialty pharmaceutical company, since May 2026. Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc. (formerly Nasdaq: GBT), a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer Inc. Prior to that, Mr. Farrow served as chief financial officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the chief financial officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from July 2010 until May 2015 which was acquired by Horizon Therapeutics in May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and chief accounting officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).
- Richard Stewart
-
Richard Stewart自2017年8月起担任公司董事长、首席执行官和董事。在我们与Achieve Life Science，Inc.合并或合并之前，Stewart先生自2015年5月Achieve Life Science，Inc.成立以来一直担任其董事长兼董事。Stewart自2009年起担任Ricanto Limited（一家制药资产优化公司）创始人和董事。Stewart先生自2016年以来一直担任Renown Pharma Limited的董事长兼首席执行官，该公司是一家专注于帕金森氏症的中枢神经系统公司。在此之前，Stewart先生于2009年担任单一用途中枢神经系统公司Huxley Pharmaceuticals，Inc.的董事长兼首席执行官，在此之前，Huxley Pharmaceuticals，Inc.被Biomarin PharmaceuticalInc.收购Stewart从2013年到2014年担任Brabant Pharma Limited（一家单一目的中枢神经系统公司）首席执行官。从2000年到2007年，他是Amarin Corporation Plc（一家中枢神经系统公司，专注于帕金森氏症和亨廷顿氏症）的联合创始人兼首席执行官。Stewart先生是SkyePharma plc（一家药物输送公司，专门从事控释制剂）的联合创始人和首席财务官，后来担任首席商务官，并从1995年到1998年担任该职位。Stewart先生持有巴斯大学（University of Bath）工商管理理学学士学位。
Richard Stewart served as Achieve Life Sciences, Inc.'s Chief Executive Officer from August 2024 to April 2026, and served as Achieve Life Sciences, Inc.'s Executive Chairman from September 2020 to August 2024. Previously, Mr. Stewart served as Chief Executive Officer from the consummation of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve in August 2017 to September 2020. Previously, Mr. Stewart was Chairman and a director of Achieve, from its founding in May 2015 to August 2017. Mr. Stewart is also a founder and has served as a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson's disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.'s acquisition by BioMarin Pharmaceutical Inc., a biotechnology company. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc., a biopharmaceutical company. He was a co founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson's disease and Huntington's disease, from 2000 to 2007. Mr. Stewart was a co founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such position from 1995 until 1998. Mr. Stewart holds a B.S. in Business Administration from the University of Bath. - Richard Stewart自2017年8月起担任公司董事长、首席执行官和董事。在我们与Achieve Life Science，Inc.合并或合并之前，Stewart先生自2015年5月Achieve Life Science，Inc.成立以来一直担任其董事长兼董事。Stewart自2009年起担任Ricanto Limited（一家制药资产优化公司）创始人和董事。Stewart先生自2016年以来一直担任Renown Pharma Limited的董事长兼首席执行官，该公司是一家专注于帕金森氏症的中枢神经系统公司。在此之前，Stewart先生于2009年担任单一用途中枢神经系统公司Huxley Pharmaceuticals，Inc.的董事长兼首席执行官，在此之前，Huxley Pharmaceuticals，Inc.被Biomarin PharmaceuticalInc.收购Stewart从2013年到2014年担任Brabant Pharma Limited（一家单一目的中枢神经系统公司）首席执行官。从2000年到2007年，他是Amarin Corporation Plc（一家中枢神经系统公司，专注于帕金森氏症和亨廷顿氏症）的联合创始人兼首席执行官。Stewart先生是SkyePharma plc（一家药物输送公司，专门从事控释制剂）的联合创始人和首席财务官，后来担任首席商务官，并从1995年到1998年担任该职位。Stewart先生持有巴斯大学（University of Bath）工商管理理学学士学位。
- Richard Stewart served as Achieve Life Sciences, Inc.'s Chief Executive Officer from August 2024 to April 2026, and served as Achieve Life Sciences, Inc.'s Executive Chairman from September 2020 to August 2024. Previously, Mr. Stewart served as Chief Executive Officer from the consummation of the merger between OncoGenex Pharmaceuticals, Inc. and Achieve in August 2017 to September 2020. Previously, Mr. Stewart was Chairman and a director of Achieve, from its founding in May 2015 to August 2017. Mr. Stewart is also a founder and has served as a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson's disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.'s acquisition by BioMarin Pharmaceutical Inc., a biotechnology company. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc., a biopharmaceutical company. He was a co founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson's disease and Huntington's disease, from 2000 to 2007. Mr. Stewart was a co founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such position from 1995 until 1998. Mr. Stewart holds a B.S. in Business Administration from the University of Bath.
- Aaron Royston
-
Aaron Royston自2023年6月起担任Attovia Therapeutics，Inc.董事会成员。自2015年11月以来，罗伊斯顿博士一直担任生命科学投资公司venBio Partners，LLC的管理合伙人。在加入venBio Partners，LLC之前，Royston博士曾于2014年7月至2015年10月在Vivo Capital LLC、2013年7月至2014年7月在Bain & Company，Inc.以及2007年7月至2008年7月在西奈山医疗中心担任过多个职位。Royston博士曾担任多家上市公司的董事会成员，包括2020年8月至2023年11月期间生物技术公司RayzeBio，Inc.（已被BMS收购）以及2021年3月至2023年1月期间生物技术公司Ventyx Biosciences, Inc.。罗伊斯顿博士拥有杜克大学生物科学学士学位，宾夕法尼亚大学医学博士和工商管理硕士学位。
Aaron Royston has served as a member of Attovia Therapeutics, Inc.'s board of directors since June 2023. Dr. Royston has been a managing partner at venBio Partners, LLC, a life sciences investment firm, since November 2015. Prior to joining venBio Partners, LLC, Dr. Royston held various positions at Vivo Capital LLC from July 2014 to October 2015, Bain & Company, Inc. from July 2013 to July 2014, and Mount Sinai Medical Center from July 2007 to July 2008. Dr. Royston has served as a member of the board of directors of several publicly traded companies, including RayzeBio, Inc. (acquired by BMS), a biotechnology company, from August 2020 to November 2023, and Ventyx Biosciences, Inc., a biotechnology company, from March 2021 until January 2023. Dr. Royston has a B.S. in Biological Sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania. - Aaron Royston自2023年6月起担任Attovia Therapeutics，Inc.董事会成员。自2015年11月以来，罗伊斯顿博士一直担任生命科学投资公司venBio Partners，LLC的管理合伙人。在加入venBio Partners，LLC之前，Royston博士曾于2014年7月至2015年10月在Vivo Capital LLC、2013年7月至2014年7月在Bain & Company，Inc.以及2007年7月至2008年7月在西奈山医疗中心担任过多个职位。Royston博士曾担任多家上市公司的董事会成员，包括2020年8月至2023年11月期间生物技术公司RayzeBio，Inc.（已被BMS收购）以及2021年3月至2023年1月期间生物技术公司Ventyx Biosciences, Inc.。罗伊斯顿博士拥有杜克大学生物科学学士学位，宾夕法尼亚大学医学博士和工商管理硕士学位。
- Aaron Royston has served as a member of Attovia Therapeutics, Inc.'s board of directors since June 2023. Dr. Royston has been a managing partner at venBio Partners, LLC, a life sciences investment firm, since November 2015. Prior to joining venBio Partners, LLC, Dr. Royston held various positions at Vivo Capital LLC from July 2014 to October 2015, Bain & Company, Inc. from July 2013 to July 2014, and Mount Sinai Medical Center from July 2007 to July 2008. Dr. Royston has served as a member of the board of directors of several publicly traded companies, including RayzeBio, Inc. (acquired by BMS), a biotechnology company, from August 2020 to November 2023, and Ventyx Biosciences, Inc., a biotechnology company, from March 2021 until January 2023. Dr. Royston has a B.S. in Biological Sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania.
- Andrew D. Goldberg
-
Andrew Goldberg自2020年8月起担任我们的董事会成员。自2016年2月以来，Goldberg博士一直担任Vivo Capital（一家全球梦百合投资公司，专注于生命科学行业）的负责人。在此之前，Goldberg博士于2014年9月至2016年2月担任麦肯锡公司（McKinsey&Company）的顾问，为制药，医疗设备和生物技术公司提供战略，并购，销售，营销和产品开发主题的服务。Goldberg博士是重症监护医学和急诊医学的美国委员会认证医师。他最近担任the Mayo Clinic College of Medicine（位于明尼苏达州罗彻斯特）的医学讲师（从2013年1月到2013年6月），在那里他也完成了重症监护医学研究金，并担任急诊内科主治医生。此前，他在Los Angeles County+University of Southern California Medical Center LAC+USC完成急诊医学住院医师培训。他的研究涉及多个领域，从创伤性脑损伤和心脏骤停到生物标志物分析和梦百合质量。他在领先的同行评审期刊上有超过25篇科学出版物，包括JAMA、Resucation和the Cleveland Clinic Journal of Medicine。Goldberg博士在华盛顿特区的乔治华盛顿大学医学院（George Washington University School of Medicine）获得医学博士学位，并在梅奥研究生院（Mayo Graduate School）获得翻译科学博士后文凭。他曾在俄勒冈健康与科学大学（Oregon Health&Science University）和亚利桑那大学（University of Arizona）担任学术和临床职务，目前在华盛顿城镇医疗基金会（Washington Township Medical Foundation）任职。
Andrew D. Goldberg has served as Achieve Life Sciences, Inc.'s Chief Executive Officer and President since April 2026. Previously, Dr. Goldberg served as a portfolio manager at Marshall Wace North America L.P., an alternative asset manager, from February 2024 to April 2026 and served as Managing Director from March 2021 until February 2024. Dr. Goldberg has served as a member of the Board of Tarsus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since August 2020 and Inquis Medical, Inc., a privately held medical device company, since February 2024. Prior to Dr. Goldberg's role at Marshall Wace, Dr. Goldberg served as a principal and subsequently partner at Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry, from February 2016 to March 2021. Prior to this, Dr. Goldberg was a consultant at McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg has also served as a board director or observer at numerous life sciences companies, including Veradermics Inc., Arcutis Biotherapeutics, Inc., Harmony Biosciences, Elektrofi, Parse Biosciences, and Forge Biologics. Dr. Goldberg is a U.S. board certified physician in both Critical Care Medicine and Emergency Medicine. He has served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. He completed Emergency Medicine residency training at Los Angeles County and University of Southern California Medical Center. Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post doctoral diploma in translational science from the Mayo Graduate School. He has held prior academic and clinical appointments at Oregon Health & Science University and the Palo Alto VA Medical Center. - Andrew Goldberg自2020年8月起担任我们的董事会成员。自2016年2月以来，Goldberg博士一直担任Vivo Capital（一家全球梦百合投资公司，专注于生命科学行业）的负责人。在此之前，Goldberg博士于2014年9月至2016年2月担任麦肯锡公司（McKinsey&Company）的顾问，为制药，医疗设备和生物技术公司提供战略，并购，销售，营销和产品开发主题的服务。Goldberg博士是重症监护医学和急诊医学的美国委员会认证医师。他最近担任the Mayo Clinic College of Medicine（位于明尼苏达州罗彻斯特）的医学讲师（从2013年1月到2013年6月），在那里他也完成了重症监护医学研究金，并担任急诊内科主治医生。此前，他在Los Angeles County+University of Southern California Medical Center LAC+USC完成急诊医学住院医师培训。他的研究涉及多个领域，从创伤性脑损伤和心脏骤停到生物标志物分析和梦百合质量。他在领先的同行评审期刊上有超过25篇科学出版物，包括JAMA、Resucation和the Cleveland Clinic Journal of Medicine。Goldberg博士在华盛顿特区的乔治华盛顿大学医学院（George Washington University School of Medicine）获得医学博士学位，并在梅奥研究生院（Mayo Graduate School）获得翻译科学博士后文凭。他曾在俄勒冈健康与科学大学（Oregon Health&Science University）和亚利桑那大学（University of Arizona）担任学术和临床职务，目前在华盛顿城镇医疗基金会（Washington Township Medical Foundation）任职。
- Andrew D. Goldberg has served as Achieve Life Sciences, Inc.'s Chief Executive Officer and President since April 2026. Previously, Dr. Goldberg served as a portfolio manager at Marshall Wace North America L.P., an alternative asset manager, from February 2024 to April 2026 and served as Managing Director from March 2021 until February 2024. Dr. Goldberg has served as a member of the Board of Tarsus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since August 2020 and Inquis Medical, Inc., a privately held medical device company, since February 2024. Prior to Dr. Goldberg's role at Marshall Wace, Dr. Goldberg served as a principal and subsequently partner at Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry, from February 2016 to March 2021. Prior to this, Dr. Goldberg was a consultant at McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg has also served as a board director or observer at numerous life sciences companies, including Veradermics Inc., Arcutis Biotherapeutics, Inc., Harmony Biosciences, Elektrofi, Parse Biosciences, and Forge Biologics. Dr. Goldberg is a U.S. board certified physician in both Critical Care Medicine and Emergency Medicine. He has served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. He completed Emergency Medicine residency training at Los Angeles County and University of Southern California Medical Center. Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post doctoral diploma in translational science from the Mayo Graduate School. He has held prior academic and clinical appointments at Oregon Health & Science University and the Palo Alto VA Medical Center.
- Lucian Iancovici
-
Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
Lucian Iancovici has served as a member of Rallybio's Board since May 2020. Dr. Iancovici is currently a Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received his B.A. in economics and an M.D., both from Tufts University. - Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
- Lucian Iancovici has served as a member of Rallybio's Board since May 2020. Dr. Iancovici is currently a Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received his B.A. in economics and an M.D., both from Tufts University.
- Nancy R. Phelan
-
Nancy R. Phelan曾担任生命科学咨询公司Trinity Life Sciences的高级副总裁兼客户参与负责人。她自2023年9月起担任专业制药公司Medexus Pharmaceuticals的董事会成员，自2018年起担任制药公司FemmePharma Consumer Healthcare的董事会成员。从2022年5月到2024年5月，Phelan女士担任Indegene的高级副总裁，Indegene是一家以技术为主导的医疗保健解决方案提供商。在此之前，她在跨国制药公司诺华集团担任越来越多的职责，包括2021年4月至2022年5月担任副总裁、业务转型、患者参与和整合营销团队负责人，以及2002年6月至2021年4月担任神经科学患者和专业服务副总裁。她于2019年4月至2020年6月担任临床阶段生物制药公司Adhera Therapeutics, Inc.的首席执行官兼秘书，并于2018年10月至2020年6月担任董事。Phelan女士获得了富兰克林马歇尔学院的荣誉学士学位，并完成了维拉诺瓦大学MBA的课程作业。她还获得了沃顿商学院高管教育和哈佛公共卫生学院的证书。
Nancy R. Phelan serves as the Senior Vice President of Marketing and Analytics for Phathom Pharmaceuticals, Inc. She previously served as Senior Vice President & Head of Customer Engagement at Trinity Life Sciences, a life sciences consultancy. She also serves as a member of the board of directors of Medexus Pharmaceuticals, a specialty pharmaceutical company, since September 2023. She also served as a board member of FemmePharma Consumer Healthcare, a pharmaceutical company, from 2018 to 2025. From May 2022 to May 2024, Ms. Phelan served as Senior Vice President of Indegene, a technology led healthcare solutions provider. Prior to that, she held roles of increasing responsibility with Novartis AG, a multinational pharmaceutical company, including as Vice President, Business Transformation, Patient Engagement and Integrated Marketing Team Lead from April 2021 to May 2022 and Vice President, Patient and Specialty Services, Neuroscience from June 2002 to April 2021. She served as Chief Executive Officer and Secretary of Adhera Therapeutics, Inc., a clinical stage biopharmaceutical company, from April 2019 to June 2020 and as a director from October 2018 to June 2020. Ms. Phelan received a B.A. with Honors from Franklin & Marshall College and completed coursework towards an M.B.A. from Villanova University. She also received certificates from Wharton Executive Education and the Harvard School of Public Health. - Nancy R. Phelan曾担任生命科学咨询公司Trinity Life Sciences的高级副总裁兼客户参与负责人。她自2023年9月起担任专业制药公司Medexus Pharmaceuticals的董事会成员，自2018年起担任制药公司FemmePharma Consumer Healthcare的董事会成员。从2022年5月到2024年5月，Phelan女士担任Indegene的高级副总裁，Indegene是一家以技术为主导的医疗保健解决方案提供商。在此之前，她在跨国制药公司诺华集团担任越来越多的职责，包括2021年4月至2022年5月担任副总裁、业务转型、患者参与和整合营销团队负责人，以及2002年6月至2021年4月担任神经科学患者和专业服务副总裁。她于2019年4月至2020年6月担任临床阶段生物制药公司Adhera Therapeutics, Inc.的首席执行官兼秘书，并于2018年10月至2020年6月担任董事。Phelan女士获得了富兰克林马歇尔学院的荣誉学士学位，并完成了维拉诺瓦大学MBA的课程作业。她还获得了沃顿商学院高管教育和哈佛公共卫生学院的证书。
- Nancy R. Phelan serves as the Senior Vice President of Marketing and Analytics for Phathom Pharmaceuticals, Inc. She previously served as Senior Vice President & Head of Customer Engagement at Trinity Life Sciences, a life sciences consultancy. She also serves as a member of the board of directors of Medexus Pharmaceuticals, a specialty pharmaceutical company, since September 2023. She also served as a board member of FemmePharma Consumer Healthcare, a pharmaceutical company, from 2018 to 2025. From May 2022 to May 2024, Ms. Phelan served as Senior Vice President of Indegene, a technology led healthcare solutions provider. Prior to that, she held roles of increasing responsibility with Novartis AG, a multinational pharmaceutical company, including as Vice President, Business Transformation, Patient Engagement and Integrated Marketing Team Lead from April 2021 to May 2022 and Vice President, Patient and Specialty Services, Neuroscience from June 2002 to April 2021. She served as Chief Executive Officer and Secretary of Adhera Therapeutics, Inc., a clinical stage biopharmaceutical company, from April 2019 to June 2020 and as a director from October 2018 to June 2020. Ms. Phelan received a B.A. with Honors from Franklin & Marshall College and completed coursework towards an M.B.A. from Villanova University. She also received certificates from Wharton Executive Education and the Harvard School of Public Health.
- Thomas Sellig
-
Thomas Sellig，自2022年1月起担任Adare Pharmaceuticals，Inc.的首席执行官，该公司是一家全球技术驱动的合同开发和制造组织。2019年7月至2021年10月，Sellig先生担任临床试验实验室服务机构LabConnect，Inc.的首席执行官。在加入LabConnect，Inc.之前，Sellig先生于2018年9月至2019年7月担任生物制药服务公司PSKW，LLC（以ConnectiveRx开展业务）的首席商务官。2014年11月至2017年8月，Selig先生担任Patheon N.V.全球销售高级副总裁，并在2017年8月收购Patheon N.V.后，继续担任生命、科学和临床研究公司Themo Fisher Scientific Inc.的全球销售高级副总裁。此前，他曾于2011年至2014年担任销售和客户服务全球副总裁，并于2007年至2011年在合同研究机构美国实验室公司控股的药物开发业务Covance担任战略合作伙伴/联盟管理副总裁。在其职业生涯的早期，Sellig先生曾在跨国消费品公司宝洁公司、制药公司Wyeth，LLC（前身为American Home Products）和药物开发公司Ascent Pediatrics，Inc.担任过各种销售和营销领导职务。Sellig先生获得了范德比尔特大学经济学学士学位和纽约大学工商管理硕士学位。
Thomas Sellig has served as the Chief Executive Officer of Adare Pharmaceuticals, Inc., a global technology driven Contract Development and Manufacturing Organization since January 2022. From July 2019 to October 2021, Mr. Sellig served as Chief Executive Officer of LabConnect, Inc., a clinical trial laboratory services organization. Prior to LabConnect, Inc., Mr. Sellig was Chief Commercial Officer at PSKW, LLC (doing business as ConnectiveRx), a biopharmaceutical services company, from September 2018 to July 2019. From November 2014 to August 2017, Mr. Sellig was Senior Vice President of Global Sales at Patheon N.V., and continued to serve as Senior Vice President of Global Sales at Thermo Fisher Scientific Inc., a life, science and clinical research company, following its acquisition of Patheon N.V. in August 2017. Previously, he served as the Global Vice President of Sales and Client Services from 2011 to 2014, and as the Vice President of Strategic Partnering/Alliance Management from 2007 to 2011 at Covance, the drug development business of Laboratory Corporation of America Holdings, a contract research organization. Early in his career, Mr. Sellig had a variety of sales and marketing leadership roles at Procter & Gamble Company, a multinational consumer goods company, Wyeth, LLC (formerly American Home Products), a pharmaceutical company, and Ascent Pediatrics, Inc., a drug development company. Mr. Sellig received his B.A. in Economics from Vanderbilt University and an M.B.A. from New York University. - Thomas Sellig，自2022年1月起担任Adare Pharmaceuticals，Inc.的首席执行官，该公司是一家全球技术驱动的合同开发和制造组织。2019年7月至2021年10月，Sellig先生担任临床试验实验室服务机构LabConnect，Inc.的首席执行官。在加入LabConnect，Inc.之前，Sellig先生于2018年9月至2019年7月担任生物制药服务公司PSKW，LLC（以ConnectiveRx开展业务）的首席商务官。2014年11月至2017年8月，Selig先生担任Patheon N.V.全球销售高级副总裁，并在2017年8月收购Patheon N.V.后，继续担任生命、科学和临床研究公司Themo Fisher Scientific Inc.的全球销售高级副总裁。此前，他曾于2011年至2014年担任销售和客户服务全球副总裁，并于2007年至2011年在合同研究机构美国实验室公司控股的药物开发业务Covance担任战略合作伙伴/联盟管理副总裁。在其职业生涯的早期，Sellig先生曾在跨国消费品公司宝洁公司、制药公司Wyeth，LLC（前身为American Home Products）和药物开发公司Ascent Pediatrics，Inc.担任过各种销售和营销领导职务。Sellig先生获得了范德比尔特大学经济学学士学位和纽约大学工商管理硕士学位。
- Thomas Sellig has served as the Chief Executive Officer of Adare Pharmaceuticals, Inc., a global technology driven Contract Development and Manufacturing Organization since January 2022. From July 2019 to October 2021, Mr. Sellig served as Chief Executive Officer of LabConnect, Inc., a clinical trial laboratory services organization. Prior to LabConnect, Inc., Mr. Sellig was Chief Commercial Officer at PSKW, LLC (doing business as ConnectiveRx), a biopharmaceutical services company, from September 2018 to July 2019. From November 2014 to August 2017, Mr. Sellig was Senior Vice President of Global Sales at Patheon N.V., and continued to serve as Senior Vice President of Global Sales at Thermo Fisher Scientific Inc., a life, science and clinical research company, following its acquisition of Patheon N.V. in August 2017. Previously, he served as the Global Vice President of Sales and Client Services from 2011 to 2014, and as the Vice President of Strategic Partnering/Alliance Management from 2007 to 2011 at Covance, the drug development business of Laboratory Corporation of America Holdings, a contract research organization. Early in his career, Mr. Sellig had a variety of sales and marketing leadership roles at Procter & Gamble Company, a multinational consumer goods company, Wyeth, LLC (formerly American Home Products), a pharmaceutical company, and Ascent Pediatrics, Inc., a drug development company. Mr. Sellig received his B.A. in Economics from Vanderbilt University and an M.B.A. from New York University.
- Reid Waldman
-
雷德·沃尔德曼是联合创始人，自2022年12月起担任首席执行官。在担任首席执行官之前，Waldman博士曾于2020年3月至2022年12月担任首席运营官。Waldman博士自2019年10月起担任董事会成员。从2019年3月至2021年6月，Waldman博士担任康涅狄格大学健康中心的临床试验住院医师，并于2018年6月至2021年6月担任皮肤科住院医师。在住院之前，Waldman医生完成了在Cedars Sinai医疗中心的实习。Waldman博士是一名获得董事会认证的皮肤科医生，并获得了米西堪萨斯城大学6年B. A./M.D.项目的学士和医学博士学位。
Reid Waldman has served as Chief Executive Officer of Veradermics, Incorporated since 2019. Dr. Waldman is a board certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a researcher authoring more than 100 publications. He earned his B.A. and his M.D. degrees from the University of Missouri Kansas City 6 Year B.A./M.D. Program and completed his dermatology residency with a "Distinction in Clinical Trials" at the University of Connecticut. - 雷德·沃尔德曼是联合创始人，自2022年12月起担任首席执行官。在担任首席执行官之前，Waldman博士曾于2020年3月至2022年12月担任首席运营官。Waldman博士自2019年10月起担任董事会成员。从2019年3月至2021年6月，Waldman博士担任康涅狄格大学健康中心的临床试验住院医师，并于2018年6月至2021年6月担任皮肤科住院医师。在住院之前，Waldman医生完成了在Cedars Sinai医疗中心的实习。Waldman博士是一名获得董事会认证的皮肤科医生，并获得了米西堪萨斯城大学6年B. A./M.D.项目的学士和医学博士学位。
- Reid Waldman has served as Chief Executive Officer of Veradermics, Incorporated since 2019. Dr. Waldman is a board certified dermatologist with more than 10 years of clinical experience. Prior to founding Veradermics, Dr. Waldman was a researcher authoring more than 100 publications. He earned his B.A. and his M.D. degrees from the University of Missouri Kansas City 6 Year B.A./M.D. Program and completed his dermatology residency with a "Distinction in Clinical Trials" at the University of Connecticut.
- Jeffrey Farrow
-
Jeffrey Farrow自2023年4月起担任商业阶段生物制药公司Tarsus Pharmaceutical，Inc.的首席财务官和首席战略官。法罗先生还担任Clover Biotherapeutics的董事会成员，他自2021年9月以来一直担任该职位。Farrow先生此前曾于2016年4月至2022年12月在生物制药公司全球血液疗法公司担任首席财务官，当时该公司被辉瑞收购。在此之前，Farrow先生在生物制药公司ZS Pharma，Inc.担任首席财务官，该公司于2015年12月被阿斯利康收购。在加入ZS制药之前，2010年1月至2015年5月被Horizon Therapeutics收购之前，他曾在商业制药公司Hyperion Therapeutics, Inc.担任首席财务官。他此前曾在药物发现和开发公司Evotec AG担任财务副总裁。在加入Evotec之前，Farrow先生曾在Renovis，Inc.担任财务副总裁兼首席会计官，这是一家药物发现和开发公司，该公司已被Evotec AG收购。在其职业生涯的早期，法罗先生在毕马威会计师事务所的审计业务中工作了七年。Farrow先生拥有加州州立大学富勒顿分校企业融资专业的工商管理学士学位，是一名注册会计师（非在职）。
Jeffrey Farrow has served as the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceutical, Inc., a commercial stage biopharmaceutical company, since April 2023. Mr. Farrow also serves as a board member of Clover Biotherapeutics, a position he has held since September 2021. Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc., a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer. Prior to that, Mr. Farrow served as Chief Financial Officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the Chief Financial Officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from January 2010 until its acquisition by Horizon Therapeutics in May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and Chief Accounting Officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive). - Jeffrey Farrow自2023年4月起担任商业阶段生物制药公司Tarsus Pharmaceutical，Inc.的首席财务官和首席战略官。法罗先生还担任Clover Biotherapeutics的董事会成员，他自2021年9月以来一直担任该职位。Farrow先生此前曾于2016年4月至2022年12月在生物制药公司全球血液疗法公司担任首席财务官，当时该公司被辉瑞收购。在此之前，Farrow先生在生物制药公司ZS Pharma，Inc.担任首席财务官，该公司于2015年12月被阿斯利康收购。在加入ZS制药之前，2010年1月至2015年5月被Horizon Therapeutics收购之前，他曾在商业制药公司Hyperion Therapeutics, Inc.担任首席财务官。他此前曾在药物发现和开发公司Evotec AG担任财务副总裁。在加入Evotec之前，Farrow先生曾在Renovis，Inc.担任财务副总裁兼首席会计官，这是一家药物发现和开发公司，该公司已被Evotec AG收购。在其职业生涯的早期，法罗先生在毕马威会计师事务所的审计业务中工作了七年。Farrow先生拥有加州州立大学富勒顿分校企业融资专业的工商管理学士学位，是一名注册会计师（非在职）。
- Jeffrey Farrow has served as the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceutical, Inc., a commercial stage biopharmaceutical company, since April 2023. Mr. Farrow also serves as a board member of Clover Biotherapeutics, a position he has held since September 2021. Mr. Farrow previously served as Chief Financial Officer of Global Blood Therapeutics, Inc., a biopharmaceutical company, from April 2016 until December 2022 when it was acquired by Pfizer. Prior to that, Mr. Farrow served as Chief Financial Officer of ZS Pharma, Inc., a biopharmaceutical company, which was acquired by AstraZeneca in December 2015. Prior to ZS Pharma, he served as the Chief Financial Officer at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, from January 2010 until its acquisition by Horizon Therapeutics in May 2015. He previously served as vice president of finance at Evotec AG, a drug discovery and development company. Prior to Evotec, Mr. Farrow served as vice president of finance and Chief Accounting Officer at Renovis, Inc., a drug discovery and development company, which was acquired by Evotec AG. Earlier in his career, Mr. Farrow spent seven years working in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).
- Chris Martin
-
Chris Martin于2024年1月至2025年10月担任生物制药公司维罗纳制药的首席商务官，该公司于2025年10月被默沙东公司收购。Martin先生此前曾担任维罗纳的其他管理职位，包括2022年1月至2023年12月的商务高级副总裁和2020年6月至2022年12月的商务副总裁。在加入Verona之前，他曾于2018年3月至2020年6月在SK Life Science担任市场营销执行总监，该公司为中枢神经系统疾病开发新疗法。在被Melinta Therapeutics收购之前，Martin先生是Cempra的营销主管。在加入Cempra之前，他曾在柳药医疗工作了10年，担任越来越有责任感的角色。Martin先生还自2025年12月起担任Oruka Therapeutics董事会成员，自2025年11月起担任Edgewise Therapeutics，Inc.董事会成员。Martin先生获得克莱姆森大学财务管理理学学士学位。
Chris Martin served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, a biopharmaceutical company, which was acquired by Merck & Co. in October 2025. Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 to December 2022. Prior to Verona, he served as Executive Director of Marketing at SK Life Science, which develops novel therapeutics for central nervous system conditions, from March 2018 to June 2020. Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra. Prior to Cempra, he worked at Salix Pharmaceuticals for 10 years in roles of increasing responsibility. Mr. Martin has also served as a member of the board of directors of Oruka Therapeutics since December 2025 and Edgewise Therapeutics, Inc. since November 2025. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University. - Chris Martin于2024年1月至2025年10月担任生物制药公司维罗纳制药的首席商务官，该公司于2025年10月被默沙东公司收购。Martin先生此前曾担任维罗纳的其他管理职位，包括2022年1月至2023年12月的商务高级副总裁和2020年6月至2022年12月的商务副总裁。在加入Verona之前，他曾于2018年3月至2020年6月在SK Life Science担任市场营销执行总监，该公司为中枢神经系统疾病开发新疗法。在被Melinta Therapeutics收购之前，Martin先生是Cempra的营销主管。在加入Cempra之前，他曾在柳药医疗工作了10年，担任越来越有责任感的角色。Martin先生还自2025年12月起担任Oruka Therapeutics董事会成员，自2025年11月起担任Edgewise Therapeutics，Inc.董事会成员。Martin先生获得克莱姆森大学财务管理理学学士学位。
- Chris Martin served as Chief Commercial Officer from January 2024 to October 2025 for Verona Pharma, a biopharmaceutical company, which was acquired by Merck & Co. in October 2025. Mr. Martin previously served in other management positions at Verona, including Senior Vice President of Commercial from January 2022 to December 2023 and Vice President of Commercial from June 2020 to December 2022. Prior to Verona, he served as Executive Director of Marketing at SK Life Science, which develops novel therapeutics for central nervous system conditions, from March 2018 to June 2020. Until its acquisition by Melinta Therapeutics, Mr. Martin was Head of Marketing at Cempra. Prior to Cempra, he worked at Salix Pharmaceuticals for 10 years in roles of increasing responsibility. Mr. Martin has also served as a member of the board of directors of Oruka Therapeutics since December 2025 and Edgewise Therapeutics, Inc. since November 2025. Mr. Martin received a Bachelor of Science in Financial Management from Clemson University.
高管简历
中英对照 | 中文 | 英文- Andrew D. Goldberg
Andrew Goldberg自2020年8月起担任我们的董事会成员。自2016年2月以来，Goldberg博士一直担任Vivo Capital（一家全球梦百合投资公司，专注于生命科学行业）的负责人。在此之前，Goldberg博士于2014年9月至2016年2月担任麦肯锡公司（McKinsey&Company）的顾问，为制药，医疗设备和生物技术公司提供战略，并购，销售，营销和产品开发主题的服务。Goldberg博士是重症监护医学和急诊医学的美国委员会认证医师。他最近担任the Mayo Clinic College of Medicine（位于明尼苏达州罗彻斯特）的医学讲师（从2013年1月到2013年6月），在那里他也完成了重症监护医学研究金，并担任急诊内科主治医生。此前，他在Los Angeles County+University of Southern California Medical Center LAC+USC完成急诊医学住院医师培训。他的研究涉及多个领域，从创伤性脑损伤和心脏骤停到生物标志物分析和梦百合质量。他在领先的同行评审期刊上有超过25篇科学出版物，包括JAMA、Resucation和the Cleveland Clinic Journal of Medicine。Goldberg博士在华盛顿特区的乔治华盛顿大学医学院（George Washington University School of Medicine）获得医学博士学位，并在梅奥研究生院（Mayo Graduate School）获得翻译科学博士后文凭。他曾在俄勒冈健康与科学大学（Oregon Health&Science University）和亚利桑那大学（University of Arizona）担任学术和临床职务，目前在华盛顿城镇医疗基金会（Washington Township Medical Foundation）任职。
Andrew D. Goldberg has served as Achieve Life Sciences, Inc.'s Chief Executive Officer and President since April 2026. Previously, Dr. Goldberg served as a portfolio manager at Marshall Wace North America L.P., an alternative asset manager, from February 2024 to April 2026 and served as Managing Director from March 2021 until February 2024. Dr. Goldberg has served as a member of the Board of Tarsus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since August 2020 and Inquis Medical, Inc., a privately held medical device company, since February 2024. Prior to Dr. Goldberg's role at Marshall Wace, Dr. Goldberg served as a principal and subsequently partner at Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry, from February 2016 to March 2021. Prior to this, Dr. Goldberg was a consultant at McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg has also served as a board director or observer at numerous life sciences companies, including Veradermics Inc., Arcutis Biotherapeutics, Inc., Harmony Biosciences, Elektrofi, Parse Biosciences, and Forge Biologics. Dr. Goldberg is a U.S. board certified physician in both Critical Care Medicine and Emergency Medicine. He has served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. He completed Emergency Medicine residency training at Los Angeles County and University of Southern California Medical Center. Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post doctoral diploma in translational science from the Mayo Graduate School. He has held prior academic and clinical appointments at Oregon Health & Science University and the Palo Alto VA Medical Center.- Andrew Goldberg自2020年8月起担任我们的董事会成员。自2016年2月以来，Goldberg博士一直担任Vivo Capital（一家全球梦百合投资公司，专注于生命科学行业）的负责人。在此之前，Goldberg博士于2014年9月至2016年2月担任麦肯锡公司（McKinsey&Company）的顾问，为制药，医疗设备和生物技术公司提供战略，并购，销售，营销和产品开发主题的服务。Goldberg博士是重症监护医学和急诊医学的美国委员会认证医师。他最近担任the Mayo Clinic College of Medicine（位于明尼苏达州罗彻斯特）的医学讲师（从2013年1月到2013年6月），在那里他也完成了重症监护医学研究金，并担任急诊内科主治医生。此前，他在Los Angeles County+University of Southern California Medical Center LAC+USC完成急诊医学住院医师培训。他的研究涉及多个领域，从创伤性脑损伤和心脏骤停到生物标志物分析和梦百合质量。他在领先的同行评审期刊上有超过25篇科学出版物，包括JAMA、Resucation和the Cleveland Clinic Journal of Medicine。Goldberg博士在华盛顿特区的乔治华盛顿大学医学院（George Washington University School of Medicine）获得医学博士学位，并在梅奥研究生院（Mayo Graduate School）获得翻译科学博士后文凭。他曾在俄勒冈健康与科学大学（Oregon Health&Science University）和亚利桑那大学（University of Arizona）担任学术和临床职务，目前在华盛顿城镇医疗基金会（Washington Township Medical Foundation）任职。
- Andrew D. Goldberg has served as Achieve Life Sciences, Inc.'s Chief Executive Officer and President since April 2026. Previously, Dr. Goldberg served as a portfolio manager at Marshall Wace North America L.P., an alternative asset manager, from February 2024 to April 2026 and served as Managing Director from March 2021 until February 2024. Dr. Goldberg has served as a member of the Board of Tarsus Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, since August 2020 and Inquis Medical, Inc., a privately held medical device company, since February 2024. Prior to Dr. Goldberg's role at Marshall Wace, Dr. Goldberg served as a principal and subsequently partner at Vivo Capital, a global healthcare investment firm that focuses exclusively on the life sciences industry, from February 2016 to March 2021. Prior to this, Dr. Goldberg was a consultant at McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies across a range of strategy, M&A, sales, marketing, and product development topics. Dr. Goldberg has also served as a board director or observer at numerous life sciences companies, including Veradermics Inc., Arcutis Biotherapeutics, Inc., Harmony Biosciences, Elektrofi, Parse Biosciences, and Forge Biologics. Dr. Goldberg is a U.S. board certified physician in both Critical Care Medicine and Emergency Medicine. He has served as an Instructor in Medicine at the Mayo Clinic College of Medicine in Rochester, MN, where he also completed a fellowship in Critical Care Medicine and served as an Attending Physician in the Department of Emergency Medicine. He completed Emergency Medicine residency training at Los Angeles County and University of Southern California Medical Center. Dr. Goldberg received his M.D. from The George Washington University School of Medicine in Washington, DC, and a post doctoral diploma in translational science from the Mayo Graduate School. He has held prior academic and clinical appointments at Oregon Health & Science University and the Palo Alto VA Medical Center.
- Mark Oki
Mark Oki自2024年12月起担任首席财务官。从2022年1月至2024年11月，Oki先生在Aytu BioPharma, Inc.担任首席财务官，该公司是一家专注于将新型疗法和消费者保健产品商业化的制药公司。从2015年到2022年1月，Oki先生担任Vivus LLC（前身为Vivus Inc.）的首席财务官，该公司是一家商业阶段的制药公司，之前在纳斯达克上市。从2006年到2015年，Oki先生曾在公开上市的专业制药公司Alexza Pharmaceuticals, Inc.担任多个职位，最近担任财务高级副总裁、首席财务官和秘书。在Alexza之前，Oki先生曾在Pharmacyclics，Inc.和因塞特医疗 Genomics，Inc.（现因塞特医疗公司）这两家生命科学公司担任越来越重要的职务。Oki先生的公共会计职业生涯始于Deloitte & Touche，LLP（现为德勤）。Oki先生获得工商管理–会计学学位，以优异成绩毕业于圣何塞州立大学，是一名注册会计师（非在职）。
Mark Oki has served as Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).- Mark Oki自2024年12月起担任首席财务官。从2022年1月至2024年11月，Oki先生在Aytu BioPharma, Inc.担任首席财务官，该公司是一家专注于将新型疗法和消费者保健产品商业化的制药公司。从2015年到2022年1月，Oki先生担任Vivus LLC（前身为Vivus Inc.）的首席财务官，该公司是一家商业阶段的制药公司，之前在纳斯达克上市。从2006年到2015年，Oki先生曾在公开上市的专业制药公司Alexza Pharmaceuticals, Inc.担任多个职位，最近担任财务高级副总裁、首席财务官和秘书。在Alexza之前，Oki先生曾在Pharmacyclics，Inc.和因塞特医疗 Genomics，Inc.（现因塞特医疗公司）这两家生命科学公司担任越来越重要的职务。Oki先生的公共会计职业生涯始于Deloitte & Touche，LLP（现为德勤）。Oki先生获得工商管理–会计学学位，以优异成绩毕业于圣何塞州立大学，是一名注册会计师（非在职）。
- Mark Oki has served as Chief Financial Officer since December 2024. From January 2022 to November 2024, Mr. Oki served as Chief Financial Officer of Aytu Biopharma, Inc., a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products. From 2015 through January 2022, Mr. Oki served as Chief Financial Officer of Vivus LLC (formerly Vivus Inc.), a commercial stage pharmaceutical company formerly listed on Nasdaq. From 2006 to 2015, Mr. Oki held several positions at Alexza Pharmaceuticals, Inc., a publicly listed specialty pharmaceutical company, most recently as Senior Vice President, Finance, Chief Financial Officer and Secretary. Before Alexza, Mr. Oki held roles of increasing responsibility at Pharmacyclics, Inc. and Incyte Genomics, Inc. (now Incyte Corporation), both life sciences companies. Mr. Oki began his career in public accounting at Deloitte & Touche, LLP (now Deloitte). Mr. Oki received his degree in Business Administration – Accounting and graduated with honors from San Jose State University and is a Certified Public Accountant (inactive).
- Erik Atkisson
Erik Atkisson自2025年10月起担任公司首席法务官。2024年1月至2025年10月，Atkisson先生担任战略生命科学顾问，为中小型生命科学公司提供法律、业务和合规建议。从2023年2月到2024年1月，Atkisson先生担任Rain Oncology Inc.的总法律顾问和首席合规官，该公司是一家临床阶段的生物技术研究公司，之前在纳斯达克上市。2021年8月至2023年2月，Atkisson先生担任Eiger BioPharmaceuticals的总法律顾问、公司秘书和首席合规官，Eiger BioPharmaceuticals是一家商业阶段的生物制药公司，以前在纳斯达克上市。自2019年8月至2021年8月，Atkisson先生担任晚期生物技术研究公司Cytokinetics公司的首席合规官和法律顾问。从2014年到2018年，Atkisson先生曾在Impax制药，LLC（现为Amneal制药）担任多个职位，这是一家商业阶段的生物制药公司，最近担任高级总监–医疗保健、商业和就业法。从2010年到2014年，Atkisson先生担任商业阶段制药公司BioMarin Pharmaceutical Inc.的高级法律顾问。Atkisson先生的职业生涯始于Bingham McCutchen LLP和Reed Smith LLP律师事务所的合伙人。Atkisson先生在哈佛大学获得学士学位，在爱丁堡大学获得理学硕士学位，在乔治敦大学法律中心获得法学博士学位。
Erik Atkisson has served as Achieve Life Sciences, Inc.'s Chief Legal Officer since October 2025. From January 2024 to October 2025, Mr. Atkisson served as a Strategic Life Sciences Consultant where he provided legal, business and compliance advice to small and mid size life sciences companies. From February 2023 through January 2024, Mr. Atkisson served as General Counsel and Chief Compliance Officer of Rain Oncology Inc., a clinical stage biotechnology research company formerly listed on Nasdaq. From August 2021 to February 2023, Mr. Atkisson served as General Counsel, Corporate Secretary and Chief Compliance Officer of Eiger BioPharmaceuticals, a commercial stage biopharmaceutical company formerly listed on Nasdaq. From August 2019 to August 2021, Mr. Atkisson served as Chief Compliance Officer and Legal Counsel of Cytokinetics, Inc., a late stage biotechnology research company. From 2014 to 2018, Mr. Atkisson held several positions at Impax Laboratories, LLC (now Amneal Pharmaceuticals), a commercial stage biopharmaceuticals company, most recently as Senior Director – Healthcare, Commercial and Employment Law. From 2010 to 2014, Mr. Atkisson served as Senior Counsel of BioMarin Pharmaceutical Inc., a commercial stage pharmaceutical company. Mr. Atkisson began his career as an associate at the law firms Bingham McCutchen LLP and Reed Smith LLP. Mr. Atkisson received his bachelor's degree from Harvard University, a Master of Science degree from The University of Edinburgh, and his Juris Doctorate from the Georgetown University Law Center.- Erik Atkisson自2025年10月起担任公司首席法务官。2024年1月至2025年10月，Atkisson先生担任战略生命科学顾问，为中小型生命科学公司提供法律、业务和合规建议。从2023年2月到2024年1月，Atkisson先生担任Rain Oncology Inc.的总法律顾问和首席合规官，该公司是一家临床阶段的生物技术研究公司，之前在纳斯达克上市。2021年8月至2023年2月，Atkisson先生担任Eiger BioPharmaceuticals的总法律顾问、公司秘书和首席合规官，Eiger BioPharmaceuticals是一家商业阶段的生物制药公司，以前在纳斯达克上市。自2019年8月至2021年8月，Atkisson先生担任晚期生物技术研究公司Cytokinetics公司的首席合规官和法律顾问。从2014年到2018年，Atkisson先生曾在Impax制药，LLC（现为Amneal制药）担任多个职位，这是一家商业阶段的生物制药公司，最近担任高级总监–医疗保健、商业和就业法。从2010年到2014年，Atkisson先生担任商业阶段制药公司BioMarin Pharmaceutical Inc.的高级法律顾问。Atkisson先生的职业生涯始于Bingham McCutchen LLP和Reed Smith LLP律师事务所的合伙人。Atkisson先生在哈佛大学获得学士学位，在爱丁堡大学获得理学硕士学位，在乔治敦大学法律中心获得法学博士学位。
- Erik Atkisson has served as Achieve Life Sciences, Inc.'s Chief Legal Officer since October 2025. From January 2024 to October 2025, Mr. Atkisson served as a Strategic Life Sciences Consultant where he provided legal, business and compliance advice to small and mid size life sciences companies. From February 2023 through January 2024, Mr. Atkisson served as General Counsel and Chief Compliance Officer of Rain Oncology Inc., a clinical stage biotechnology research company formerly listed on Nasdaq. From August 2021 to February 2023, Mr. Atkisson served as General Counsel, Corporate Secretary and Chief Compliance Officer of Eiger BioPharmaceuticals, a commercial stage biopharmaceutical company formerly listed on Nasdaq. From August 2019 to August 2021, Mr. Atkisson served as Chief Compliance Officer and Legal Counsel of Cytokinetics, Inc., a late stage biotechnology research company. From 2014 to 2018, Mr. Atkisson held several positions at Impax Laboratories, LLC (now Amneal Pharmaceuticals), a commercial stage biopharmaceuticals company, most recently as Senior Director – Healthcare, Commercial and Employment Law. From 2010 to 2014, Mr. Atkisson served as Senior Counsel of BioMarin Pharmaceutical Inc., a commercial stage pharmaceutical company. Mr. Atkisson began his career as an associate at the law firms Bingham McCutchen LLP and Reed Smith LLP. Mr. Atkisson received his bachelor's degree from Harvard University, a Master of Science degree from The University of Edinburgh, and his Juris Doctorate from the Georgetown University Law Center.
- Craig Donnelly
Craig Donnelly，自2025年9月起担任Achieve Life Sciences, Inc.首席运营官。2024年3月至2025年9月，Donnelly先生担任Achieve Life Sciences, Inc.执行副总裁、CMC和监管CMC；2023年3月至2024年2月，担任Achieve Life Sciences, Inc.高级副总裁、CMC和监管CMC。在加入Achieve Life Sciences, Inc.之前，2022年10月至2023年2月，Donnelly先生曾在临床阶段生物制药公司NUCana plc担任CMC和监管CMC副总裁，并于2021年1月至2022年10月担任CMC和监管事务高级总监。此前，唐纳利先生曾在合同研究机构ICON plc（前身为Mapi）和跨国医疗保健公司F. Hoffmann-La Roche Ltd.担任CMC和监管职能部门的高级职务。在晋升为项目领导职务之前，他在辉瑞公司开始了他的职业生涯，担任分析化学家，并在合同开发和制造组织Almac Sciences担任团队负责人。Donnelly先生拥有桑德兰大学化学和药物科学荣誉学士学位。
Craig Donnelly has served as Achieve Life Sciences, Inc.'s Chief Operations Officer since September 2025. From March 2024 to September 2025, Mr. Donnelly served as Achieve Life Sciences, Inc.'s Executive Vice President, CMC and Regulatory CMC, and from March 2023 to February 2024, he served as Achieve Life Sciences, Inc.'s Senior Vice President, CMC and Regulatory CMC. Prior to joining Achieve Life Sciences, Inc., from October 2022 to February 2023, Mr. Donnelly served as Vice President, CMC and Regulatory CMC at NuCana plc, a clinical stage biopharmaceutical company, and as Senior Director, CMC and Regulatory Affairs, from January 2021 to October 2022. Previously, Mr. Donnelly held senior roles in CMC and regulatory functions at ICON plc (formerly Mapi), a contract research organization, and F. Hoffmann La Roche Ltd., a multinational healthcare company. He began his career at Pfizer Inc. as an analytical chemist before advancing to a project leadership role, and served as a Team Leader at Almac Sciences, a contract development and manufacturing organization. Mr. Donnelly holds a Bachelor's degree with Honors in Chemical and Pharmaceutical Sciences from the University of Sunderland.- Craig Donnelly，自2025年9月起担任Achieve Life Sciences, Inc.首席运营官。2024年3月至2025年9月，Donnelly先生担任Achieve Life Sciences, Inc.执行副总裁、CMC和监管CMC；2023年3月至2024年2月，担任Achieve Life Sciences, Inc.高级副总裁、CMC和监管CMC。在加入Achieve Life Sciences, Inc.之前，2022年10月至2023年2月，Donnelly先生曾在临床阶段生物制药公司NUCana plc担任CMC和监管CMC副总裁，并于2021年1月至2022年10月担任CMC和监管事务高级总监。此前，唐纳利先生曾在合同研究机构ICON plc（前身为Mapi）和跨国医疗保健公司F. Hoffmann-La Roche Ltd.担任CMC和监管职能部门的高级职务。在晋升为项目领导职务之前，他在辉瑞公司开始了他的职业生涯，担任分析化学家，并在合同开发和制造组织Almac Sciences担任团队负责人。Donnelly先生拥有桑德兰大学化学和药物科学荣誉学士学位。
- Craig Donnelly has served as Achieve Life Sciences, Inc.'s Chief Operations Officer since September 2025. From March 2024 to September 2025, Mr. Donnelly served as Achieve Life Sciences, Inc.'s Executive Vice President, CMC and Regulatory CMC, and from March 2023 to February 2024, he served as Achieve Life Sciences, Inc.'s Senior Vice President, CMC and Regulatory CMC. Prior to joining Achieve Life Sciences, Inc., from October 2022 to February 2023, Mr. Donnelly served as Vice President, CMC and Regulatory CMC at NuCana plc, a clinical stage biopharmaceutical company, and as Senior Director, CMC and Regulatory Affairs, from January 2021 to October 2022. Previously, Mr. Donnelly held senior roles in CMC and regulatory functions at ICON plc (formerly Mapi), a contract research organization, and F. Hoffmann La Roche Ltd., a multinational healthcare company. He began his career at Pfizer Inc. as an analytical chemist before advancing to a project leadership role, and served as a Team Leader at Almac Sciences, a contract development and manufacturing organization. Mr. Donnelly holds a Bachelor's degree with Honors in Chemical and Pharmaceutical Sciences from the University of Sunderland.
- Mark Rubinstein
Mark Rubinstein，自2025年10月起担任Achieve Life Sciences, Inc.首席医疗官。2024年9月至2025年10月，鲁宾斯坦博士担任Achieve Life Sciences, Inc.副总裁、医疗事务主管，并于2024年6月至2024年9月担任公司医疗事务顾问。在加入Achieve之前，从2022年5月到2024年6月，鲁宾斯坦博士在戒烟产品公司Blip担任医疗事务主管。2019年7月至2022年5月，他在电子烟公司Juul Labs，Inc.担任全球科学事务和临床运营副总裁。从2003年到2019年，鲁宾斯坦博士担任加州大学旧金山分校（UCSF）儿科系教授，现在是儿科名誉教授。鲁宾斯坦博士在耶鲁大学医学院获得医学博士学位，并在耶鲁-纽黑文医院完成了内科住院医师实习。他获得了内科和青少年医学的董事会认证。
Mark Rubinstein has served as Achieve Life Sciences, Inc.'s Chief Medical Officer since October 2025. From September 2024 to October 2025, Dr. Rubinstein served as Achieve Life Sciences, Inc.'s Vice President, Head of Medical Affairs, and from June 2024 to September 2024, he served as a Medical Affairs consultant to the Company. Prior to joining Achieve, from May 2022 to June 2024, Dr. Rubinstein served as Head of Medical Affairs at Blip, a smoking cessation products company. From July 2019 to May 2022, he served as Vice President, Global Scientific Affairs and Clinical Operations at Juul Labs, Inc., an electronic cigarette company. From 2003 to 2019, Dr. Rubinstein served as a Professor in the Department of Pediatrics at the University of California, San Francisco (UCSF), and is now Professor Emeritus of Pediatrics. Dr. Rubinstein earned his M.D. from Yale School of Medicine and completed his Internal Medicine residency at Yale–New Haven Hospital. He is board certified in Internal Medicine and Adolescent Medicine.- Mark Rubinstein，自2025年10月起担任Achieve Life Sciences, Inc.首席医疗官。2024年9月至2025年10月，鲁宾斯坦博士担任Achieve Life Sciences, Inc.副总裁、医疗事务主管，并于2024年6月至2024年9月担任公司医疗事务顾问。在加入Achieve之前，从2022年5月到2024年6月，鲁宾斯坦博士在戒烟产品公司Blip担任医疗事务主管。2019年7月至2022年5月，他在电子烟公司Juul Labs，Inc.担任全球科学事务和临床运营副总裁。从2003年到2019年，鲁宾斯坦博士担任加州大学旧金山分校（UCSF）儿科系教授，现在是儿科名誉教授。鲁宾斯坦博士在耶鲁大学医学院获得医学博士学位，并在耶鲁-纽黑文医院完成了内科住院医师实习。他获得了内科和青少年医学的董事会认证。
- Mark Rubinstein has served as Achieve Life Sciences, Inc.'s Chief Medical Officer since October 2025. From September 2024 to October 2025, Dr. Rubinstein served as Achieve Life Sciences, Inc.'s Vice President, Head of Medical Affairs, and from June 2024 to September 2024, he served as a Medical Affairs consultant to the Company. Prior to joining Achieve, from May 2022 to June 2024, Dr. Rubinstein served as Head of Medical Affairs at Blip, a smoking cessation products company. From July 2019 to May 2022, he served as Vice President, Global Scientific Affairs and Clinical Operations at Juul Labs, Inc., an electronic cigarette company. From 2003 to 2019, Dr. Rubinstein served as a Professor in the Department of Pediatrics at the University of California, San Francisco (UCSF), and is now Professor Emeritus of Pediatrics. Dr. Rubinstein earned his M.D. from Yale School of Medicine and completed his Internal Medicine residency at Yale–New Haven Hospital. He is board certified in Internal Medicine and Adolescent Medicine.